A blood test for more than 50 types of cancer could significantly boost early detection and speed up diagnosis, according to a new study.

Made by U.S. pharmaceutical company Grail, the Galleri test aims to find fragments of DNA in a person’s blood that can indicate the presence of a cancerous tumor. Among the cancers that the test can detect, many have no current screening programs.

The PATHFINDER 2 study included more than 36,000 people aged 50 and older who had no cancer symptoms. In participants who were followed for more than a year, the test caught some 40.4% of cancer cases. For those who got a positive result on the Galleri test, 61.6% of them went on to be diagnosed with cancer—an improvement over previous trials of the test.

The results were presented on Saturday at the Europea

See Full Page